{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:56:49Z","timestamp":1769824609080,"version":"3.49.0"},"reference-count":57,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>Mifepristone is an anti\u2010progestational drug that is the first component of the standard medical abortion regimen. For women who take mifepristone and then do not take misoprostol, which is the second component of the medical abortion regimen, it is possible that their pregnancy may continue to live birth. Since mifepristone is commonly used for medical abortion up to 9\u201310\u2009weeks gestation, any adverse or teratogenic effects on the developing embryo\/fetus must be considered, given exposure during the critical time of its development and organogenesis. Toxicology and teratology reports have cited studies demonstrating teratogenic effect of mifepristone in some animals. Current clinical guidelines for women exposed to mifepristone in the first trimester of pregnancy state that it is not known to be teratogenic based on limited published evidence from humans. The aim of this narrative systematic review was to investigate embryonic\/fetal exposure to mifepristone and any association with congenital or fetal anomalies. This study was conducted by systematic searches of health databases from inception to February 2024. The references of relevant citations were manually searched to retrieve any additional citations not captured in database searching. Congenital anomalies and adverse outcomes were encountered at various doses of mifepristone exposure. A number of the congenital anomalies encountered in this review were explained by circumstances other than exposure to mifepristone. The present systematic review did not find data to support mifepristone being implicated as a teratogen.<\/jats:p>","DOI":"10.1002\/cpt.3392","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T07:15:48Z","timestamp":1721891748000},"page":"1207-1216","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Congenital and Fetal Effects After Mifepristone Exposure and Continuation of Pregnancy: A Systematic Review"],"prefix":"10.1002","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0023-4275","authenticated-orcid":false,"given":"Joseph V.","family":"Turner","sequence":"first","affiliation":[{"name":"School of Rural Medicine University of New England  Armidale New South Wales Australia"},{"name":"Faculty of Medicine University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2690-3753","authenticated-orcid":false,"given":"Deborah","family":"Garratt","sequence":"additional","affiliation":[{"name":"School of Rural Medicine University of New England  Armidale New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4504-3453","authenticated-orcid":false,"given":"Anna","family":"Barwick","sequence":"additional","affiliation":[{"name":"School of Health\u2014Pharmacy University of New England  Armidale New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2044-8681","authenticated-orcid":false,"given":"Lucas A.","family":"McLindon","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5240-8217","authenticated-orcid":false,"given":"M. Joy","family":"Spark","sequence":"additional","affiliation":[{"name":"School of Health\u2014Pharmacy University of New England  Armidale New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-4946","authenticated-orcid":false,"given":"Angela","family":"Smith","sequence":"additional","affiliation":[{"name":"Hunter New England Local Health District, NSW Health  Newcastle New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2015.01.005"},{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.12608"},{"key":"e_1_2_8_3_1","article-title":"Medical methods for first trimester abortion","volume":"5","author":"Zhang J.","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.48.1.129"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-02-20-5223"},{"key":"e_1_2_8_6_1","unstructured":"MifepristoneDrug Bank Online Internet 2021."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903535880"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198612183152501"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(87)90116-8"},{"key":"e_1_2_8_10_1","first-page":"159","article-title":"Uses of misoprostol in obstetrics and gynecology","volume":"2","author":"Allen R.","year":"2009","journal-title":"Rev. Obstet. Gynecol."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30315-6"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss7009a1"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss7110a1"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2019.05.006"},{"key":"e_1_2_8_15_1","first-page":"3","article-title":"A case series detailing the successful reversal of the effects of mifepristone using progesterone","volume":"33","author":"Delgado G.","year":"2018","journal-title":"Issues Law Med."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph10083465"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17197134"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-019-1596-2"},{"key":"e_1_2_8_19_1","volume-title":"TERIS","author":"REPROTOX","year":"2014"},{"key":"e_1_2_8_20_1","unstructured":"(2016). Mifepristone Exposure in PregnancyUK Teratology Information Service (2016)."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(90)90129-J"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0684.1994.tb00293.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004082"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12147"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2014.03.002"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12687-023-00642-2"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.07.010"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10012"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-8531(98)90008-8"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/338110d0"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91490-L"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92629-G"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60300-5"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G481"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000095844"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R252"},{"key":"e_1_2_8_37_1","first-page":"21","article-title":"A case series detailing the successful reversal of the effects of mifepristone using progesterone","volume":"33","author":"Delgado G.","year":"2018","journal-title":"Issues Law Med."},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91792-9"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.09.002"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-021-03907-1"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/13625187.2017.1412424"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1614394"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2006.03.015"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806253382604"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084715"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0845-1"},{"key":"e_1_2_8_47_1","first-page":"562","article-title":"Smith's recognizable patterns of human malformation, 6th edition","volume":"92","author":"Stein R.A.","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"e_1_2_8_48_1","volume-title":"Neural Tube Defects","author":"Shimony N.","year":"2018"},{"key":"e_1_2_8_49_1","volume-title":"Intestinal Atresia","author":"Wesson D.","year":"2021"},{"key":"e_1_2_8_50_1","volume-title":"StatPearls","author":"Akhtar F.","year":"2021"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.14503\/THIJ-14-4256"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2002.02034.x"},{"key":"e_1_2_8_53_1","article-title":"Chaos syndrome","volume":"3","author":"Mudaliyar U.S.","year":"2017","journal-title":"BJR Case Rep."},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/ojls\/15.1.109"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2016-134236"},{"key":"e_1_2_8_56_1","article-title":"Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta\u2010epidemiological study","volume":"1","author":"Toews I.","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S314959"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T14:47:22Z","timestamp":1729003642000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/cpt.3392"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3392","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"2024-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}